Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 17 11 2017
medline: 10 1 2020
entrez: 17 11 2017
Statut: ppublish

Résumé

Volumetric MRI surrogate markers of disease progression are lacking. To establish cut-off values of brain volume loss able to discriminate between healthy controls and MS patients. In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study. A total of 11,438 MRI scans performed on the same MRI scanner with the same protocol were analysed. Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated. We investigated cut-offs able to discriminate between healthy controls and MS patients. At a predefined specificity of 90%, the annualised percentage change cut-off of corpus callosum volume (-0.57%) was able to distinguish between healthy controls and patients with the highest sensitivity (51% in CIS, 48% in RRMS and 42% in SPMS patients). Lower sensitivities (22%-49%) were found for cut-offs of whole brain, grey matter and thalamic volume loss. Among CIS and RRMS patients, cut-offs were associated with greater accumulation of disability. We identified cut-offs of annualised global and regional brain volume loss rates able to discriminate between healthy controls and MS patients.

Sections du résumé

BACKGROUND
Volumetric MRI surrogate markers of disease progression are lacking.
OBJECTIVE
To establish cut-off values of brain volume loss able to discriminate between healthy controls and MS patients.
METHODS
In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study. A total of 11,438 MRI scans performed on the same MRI scanner with the same protocol were analysed. Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated. We investigated cut-offs able to discriminate between healthy controls and MS patients.
RESULTS
At a predefined specificity of 90%, the annualised percentage change cut-off of corpus callosum volume (-0.57%) was able to distinguish between healthy controls and patients with the highest sensitivity (51% in CIS, 48% in RRMS and 42% in SPMS patients). Lower sensitivities (22%-49%) were found for cut-offs of whole brain, grey matter and thalamic volume loss. Among CIS and RRMS patients, cut-offs were associated with greater accumulation of disability.
CONCLUSION
We identified cut-offs of annualised global and regional brain volume loss rates able to discriminate between healthy controls and MS patients.

Identifiants

pubmed: 29143562
doi: 10.1177/1352458517742739
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

541-553

Auteurs

Tomas Uher (T)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Manuela Vaneckova (M)

Department of Radiodiagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Jan Krasensky (J)

Department of Radiodiagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Lukas Sobisek (L)

Department of Statistics and Probability, University of Economics-Prague, Prague, Czech Republic.

Michaela Tyblova (M)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Jana Volna (J)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Zdenek Seidl (Z)

Department of Radiodiagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Niels Bergsland (N)

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA/IRCCS 'S. Maria Nascente', Don Carlo Gnocchi Foundation, Milan, Italy.

Michael G Dwyer (MG)

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.

Robert Zivadinov (R)

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA/Translational Imaging Center, Clinical and Translational Science Institute, University at Buffalo, The State University of New York, Buffalo, NY, USA.

Nicola De Stefano (N)

Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

Maria Pia Sormani (MP)

Department of Health Science, University of Genoa, Genoa, Italy.

Eva Kubala Havrdova (EK)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Dana Horakova (D)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH